Related Experiment Videos
Turn-of-the-century ethical issues in child psychiatric research
1Department of Psychiatry, Ohio State University, 1670 Upham Drive, Columbus, OH 43210, USA. Arnold.6@osu.edu
Insights
Preschoolers need ethical research guidelines for psychoactive drug trials due to developmental vulnerability. Parental consent is key, with considerations for assent and potential dissent in pediatric pharmacologic studies.
Area of Science:
- Pediatric pharmacology
- Developmental neuroscience
- Bioethics
Background:
- Increased psychoactive drug prescriptions for preschoolers raise concerns about safety and efficacy.
- Preschoolers' rapidly developing brains require specialized research considerations.
- Ethical challenges in pediatric research, particularly for children with mental disorders, are significant.
Purpose of the Study:
- To address the ethical complexities of conducting pharmacologic research in preschoolers.
- To establish guidelines for informed consent, assent, and dissent in pediatric drug trials.
- To evaluate the justification for placebo controls and non-pharmacologic treatment preceding drug trials in this age group.
Main Methods:
- Review of ethical considerations for research involving vulnerable populations.
- Analysis of parental informed consent requirements for preschoolers.
- Examination of the role of assent and dissent in pediatric research participation.
- Discussion of age-appropriate subject recompense and risk insurance.
- Evaluation of the appropriateness of placebo controls and non-pharmacologic interventions.
Main Results:
- Parental informed consent is crucial for preschoolers due to their cognitive limitations in understanding risks and benefits.
- The capacity for assent or dissent in preschoolers is questionable, potentially allowing parental consent to override dissent in certain research scenarios.
- Placebo controls are justifiable given the limited evidence base for existing treatments in preschoolers.
- Non-pharmacologic interventions should precede drug trials to identify potential responders and minimize drug exposure risks.
Conclusions:
- Ethical frameworks must be adapted for preschool pharmacologic research, prioritizing child protection.
- Parental consent, alongside careful consideration of assent/dissent, is paramount.
- Structured research protocols, including non-pharmacologic trials before drug administration, are essential for safe and effective pediatric psychopharmacology.
Abstract:
National concern in 2000 about increased psychoactive drug prescription for preschoolers accentuated the 1990s thrust for more pharmacologic research in children. Preschoolers are prescribed potent drugs without adequate evidence for efficacy or safety at this plastic age of the rapidly developing brain. Implementation of needed preschool research poses special ethical complications. Children with mental disorder qualify for special protection under both rubrics. Parental informed consent is crucial for preschoolers, who appear incapable of assent because of their preoperational, magical, animistic, egocentric thinking, with inability to comprehend relative risks and benefits. Whether they can dissent is an open question. Possibly for research with direct benefit outweighing the risk, parental permission/consent could override attempted preschooler dissent. Subject recompense should be adjusted for age differences in perception of amount, although parent reimbursement needs to be realistic. Insurance for research risk is desirable. Placebo controls appear justified for preschoolers because there is little evidence base to say that a proven effective treatment already exists. Disruptive behavior disorders, including attention-deficit/hyperactivity, have enough evidence of preschool diagnostic validity to justify therapeutic trials. In preschool pharmacologic research, a brief trial of a nonpharmacologic treatment should precede the drug trial to ensure that placebo responders and responders to the alternative treatment are not exposed to drug risk.